Keywords: aeterna, zentaris, loss, up, costs, canadian, drugmaker

AEterna Zentaris' loss up 85% on R&D costs

Article | 30 March 2009

Print This

Canadian drugmaker AEterna Zentaris' 2008 loss jumped 85% on decreased turnover and increased R&D expenses for its lead candidate cetrorelix.

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in